AbC-19 Rapid Neutralising Antibody Test

This product is available for professional use only.

We are required to vet our customers’ eligibility before placing an order for this product.

We kindly ask you to fill the verification form by clicking the button below. A member of our team will get back to you asap to confirm your details and help place the order for you.

Price: £25

Driving a return back to normal life

AbC-19™ is a rapid antibody test used for the detection of SARS-CoV-2 (COVID-19) neutralising antibodies in response to infection or following vaccination.

Detect SARS-CoV-2 neutralising antibodies from a small finger prick of blood in only 20 minutes. Show whether someone has produced an immune response to COVID-19 infection or vaccination in multiple testing locations.

AbC-19™ is a lateral flow test CE marked for use by healthcare professionals across the UK and EU.

The AbC-19™ Antibody Rapid Test can be deployed across populations and has the potential to inform vaccination programmes and health policy by showing:

  • How COVID-19 infection spreads through communities,
  • Where and why immunity to COVID-19 might be developing,
  • How mass-immunisation campaigns could be designed.

Why use AbC-19™ Rapid Test?

  • Confirms the presence of SARS-CoV-2 IgG neutralising antibodies in a small blood sample,
  • Sensitivity: 98.03%, Specificity: 99.56%*,
  • Minimal operator training required,
  • CE marked for use by healthcare professionals,
  • For use in multiple testing locations such as workplaces, pharmacies or doctors’ surgeries,
  • 24/7 customer support helpline,

AbC-19™ Rapid Test and Vaccines

Vaccines “train” the immune system by using harmless viruses that have been altered to resemble dangerous ones. In the case of the SARS-CoV-2 vaccine, developers have focused on mimicking the Spike protein. Three of the leading vaccine candidates all feature full-length SARS-CoV-2 spike trimers: Oxford University / AstraZeneca, Pfizer / BioNTeh, and Moderna.

Professor Lawrence S. Young, Virologist at University of Warwick Medical School:

"The AbC-19™ Rapid Test targets the IgG antibodies to the full spike protein of the SARS-CoV-2 virus and therefore has the potential to help identify the immune system’s response to the current three Medicines and Healthcare products Regulatory Agency (MHRA) approved vaccines. The assay could help establish whether people’s immune systems are responding to the vaccine in the right way, and, ultimately, could be predictive of a protective immune response.”

Additional information

Product Name

AbC-19 Rapid Neutralising Antibody Test


98.03%, Specificity: 99.56%


CE marked for use by healthcare professionals

Watch Instruction and Information Video